BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tazbentetol (SPG302) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tazbentetol (SPG302)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07325591-789@assetmemo.bio
DTSTAMP:20261121T005932Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tazbentetol (SPG302): Phase 2/3 readout est. (NCT07325591)
DESCRIPTION:Tazbentetol (SPG302)\, phase 2/3\, Amyotrophic Lateral Sclerosi
 s.\nStudy: Efficacy and Safety of Tazbentetol in ALS Participants\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tazbentetol-spg302#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07325591
URL:https://assetmemo.bio/drug/tazbentetol-spg302#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
